Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Squamous Intraepithelial Lesions 2Anus Neoplasms 2Vulvar Neoplasms 1Vulvar High Grade Squamous Intraepithelial Lesion (HSIL) 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Recurrence 1Penile Neoplasms 1Neoplasms 1Neoplasm Metastasis 1HIV Seropositivity 1Anal Canal Carcinoma 1

Interventions

VGX-3100 1Imiquimod 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Vulvar High Grade Squamous Intraepithelial Lesion (HSIL) × VGX-3100 × Clear all
NCT03180684 2023-08-25

Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)

Inovio Pharmaceuticals

Phase 2 Completed
33 enrolled 19 charts
Gynecologic

Vulvar High Grade Squamous Intraepithelial Lesion (HSIL)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡